FDA warns Daxal Cosmetics for refusing records on over-the-counter drugs, including toothpaste, at risk for diethylene glycol and ethylene glycol contamination.
What happened
FDA reviewed import records showing multiple shipments of drug products into the United States that declared Daxal Cosmetics Private Limited as the drug manufacturer. FDA sent records requests on November 15 and November 23, 2022, and a follow-up written request on December 3, 2022; delivery was confirmed, but the firm did not respond. FDA placed all drugs and drug products manufactured by the firm on Import Alert 66-79, an FDA list that allows detention of shipments, on January 18, 2023.
What FDA found
The firm did not answer FDA's November 15, 2022 electronic request for records and other information about drugs it registered as manufacturing.
section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4)The firm did not answer a second email request, a follow-up written request, or a December 2, 2022 phone discussion with its former U.S. agent.
section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4)The firm refused to permit access to or copying of records required by section 704(a), which is a prohibited act.
section 301(e) of the FD&C Act, 21 U.S.C. 331(e)
What FDA wants
FDA tells the firm to respond in writing within 15 working days. The firm may provide information for FDA to consider or request an FDA inspection.
Who should pay attention
- brands that import over-the-counter drugs such as toothpaste from this manufacturer
- companies buying drug ingredients at risk for diethylene glycol or ethylene glycol substitution
- U.S. importers and distributors of over-the-counter drug products
This is a summary. Read the original letter on fda.gov.